While diabetes has traditionally been the focus of blood glucose management, Afon Technology is encouraging a shift to a broader perspective.
The company believes that its Glucowear technology is positioned to revolutionise continuous glucose monitoring (CGM) by empowering those with prediabetes to make informed choices and potentially prevent the onset of Type 2 diabetes.
Currently, the only CGMs available are at best minimally invasive, using a small needle to introduce a sensor under the skin. However, the Glucowear device is non-invasive, utilising safe, ultra-low power RF/microwaves for blood glucose measurements. The wearable wrist device offers users the ability to track blood glucose fluctuations seamlessly, providing real-time feedback through a smartphone companion app. By checking their Glucowear before and after meals, exercise, and other daily activities, users can understand how their choices impact blood sugar levels, fostering a proactive and preventative approach to health.
To find out more, CLICK HERE.
